{"entity":{"id":"nct07333287","kind":"trial","name":"A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Emboli","aka":[],"tldr":"A phase 2 trial in pancreatic cancer, run by Shandong Provincial Hospital, not yet recruiting.","summary":"A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors. is a phase 2, interventional study registered as NCT07333287 by Shandong Provincial Hospital, with a registry enrolment figure of 38 participants, started 2026-02-01 and due to reach its primary completion in 2027-02-28. Interventions recorded: Interventional; Targeted Therapy (anti-VEGF); Immunotherapy + Targeted Therapy; Immunotherapy + Targeted Therapy + Chemotherapy; This cycle is repeated every 21 days.. Conditions listed: Pancreatic Cancer Liver Metastases; Immunotherapy-naive. Primary outcome: Progression-Free Survival（PFS）. Pancreatic eligibility wording from the registry: \"Histologically or cytologically confirmed, previously untreated unresectable pancreatic ductal adenocarcinoma with liver metastases (TNM stage: IV)\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07333287","url":"https://clinicaltrials.gov/study/NCT07333287"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07333287","phase":"2","setting":"A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors.","sponsor":"Shandong Provincial Hospital","enrolled":38,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07333287/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}